Stryker stock falls as Canaccord cuts its target to USD 385
Published on 09/18/2026 at 15:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Stryker Corp. stock (ISIN US8636671013) lost 1.63 percent to USD 280.13 on September 17, 2026, while the latest analyst note cut the price target to USD 385 from USD 400. The same note pointed to manufacturing problems as the reason for the downgrade.
Target cut meets a weak tape
According to Investing.com on September 17, 2026, Canaccord Genuity lowered its target to USD 385 from USD 400 and kept a Buy rating on Stryker. The move came after a run of weaker sentiment around the medical technology group.
MarketBeat said on September 18, 2026 that Stryker's average rating is Moderate Buy, with an average price target of USD 378.75. In the same coverage, the consensus upside to that average target is 33.61 percent from the last close of USD 280.13.
Guidance still matters
According to MarketBeat on September 18, 2026, Stryker last posted quarterly earnings on July 30, 2026 and reported EPS of USD 3.69, above the consensus estimate of USD 3.49 by USD 0.20. The same update says FY 2026 guidance stands at EPS of USD 14.950 to USD 15.100.
As MarketBeat reports, the company also declared a quarterly dividend of USD 0.88 a share, with an ex-dividend date of September 30, 2026.
Share price backdrop
Stryker stock closed at USD 280.13 on September 17, 2026, down 1.63 percent on the day. MarketBeat-linked market data also puts the current consensus target at USD 378.75, which keeps the shares below that level by USD 98.62.
Stryker stock at a glance
- Company: Stryker Corp.
- ISIN: US8636671013
- Ticker: SYK
- Trading venue: NYSE
- Price (as of September 17, 2026): USD 280.13
- Market capitalization: USD 107.98 billion
- Sector / Industry: Healthcare / Medical Devices
- Index membership: S&P 500
